Cellares, TScan to assess automated manufacturing of TSC-101 therapy

Cellares and TScan Therapeutics have entered a deal to assess automated manufacturing for TScan’s TSC-101 therapy in AML and MDS patients. Under the agreement, Cellares will use its Cell Shuttle and Cell Q systems to automate TSC-101 manufacturing processes. With the agreement, TCR-engineered T cell therapies such as TSC-101 become part of Cellares’ automated platform portfolio. Credit: PeopleImages / Shutterstock.com. Cellares and TScan Therapeutics have entered an agreement to examine the use of automated manufacturing for TScan’s TSC-101 therapy in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). The collaboration aims to conduct a full technical and operational…

Source: Pharmaceutical Technology